Synergy Pharma (SGYP) Reports Q1 Loss of $0.31/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. PEP
5. T
6. CVS
7. SPY
8. UNH
9. SBUX
10. AXP

Go back to Synergy Pharma (SGYP) Reports Q1 Loss of $0.31/Share

Synergy Pharmaceuticals Reports First Quarter 2017 Financial Results and Business Update

May 10, 2017 4:54 PM EDT

Received FDA Approval of TRULANCE (plecanatide) for the Treatment of Adults with Chronic Idiopathic Constipation (CIC); Initiated Promotional Efforts for TRULANCE in March 2017 Submitted Supplemental New Drug Application (sNDA) for TRULANCE for the Treatment of Adults with Irritable Bowel Syndrome with Constipation (IBS-C) Extended TRULANCE Exclusivity Protection with the Issuance of Three New Patents Highlighted New Data for TRULANCE at Digestive Disease Week (DDW) 2017

NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company... More